Received: 14 Jan. 2026 | Revised: 15 Feb. 2026 | Accepted: 30 March. 2026

Research Article

ISBN: 978-81-995400-3-3

"ROLE OF ARTIFICIAL INTELLIGENCE AND AUTOMATION IN PHARMACEUTICAL QUALITY ASSURANCE."

Nilesh Y. Jadhav[1*], Tanaya S. Ware[1], Amruta J. Karande[1], Vaishnavi A. Bhosale[1], Amol B. Khumbhar[2], Pravin J. Patil[1]

AFFLIATIONS:

1. Department of Pharmaceutical Quality Assurance, RJSPM's College of Pharmacy, Dudulgaon, Pune, Maharashtra, India.
2. Department of Pharmaceutics, RJSPM's College of Pharmacy, Dudulgaon, Pune, Maharashtra, India.

CORRESPONDENCE:
Dr. Nilesh Y. Jadhav
EMAILID:
drnilesh26@gmail.com
FUNDING INFORMATION:
Not Applicable

ABSTRACT:
Pharmaceutical Quality Assurance (QA) is fundamental to ensuring the safety, efficacy, and regulatory compliance of medicinal products throughout their lifecycle. The rapid advancement of artificial intelligence (AI) and automation technologies under the paradigm of Pharma 4.0 has significantly transformed traditional QA systems, enabling a shift from reactive quality control to predictive and preventive quality management. This review critically examines the evolving role of AI and automation in pharmaceutical quality assurance, with emphasis on their applications in manufacturing oversight, in-process quality control, visual inspection, data integrity, and regulatory compliance. AI-driven tools such as machine learning, computer vision, natural language processing, predictive analytics, and anomaly detection enhance real-time monitoring, defect identification, root-cause analysis, and decision-making accuracy while minimizing human error and operational variability. Automation technologies including robotic process automation, electronic batch records, manufacturing execution systems, laboratory information management systems, and digital validation platforms further strengthen compliance with Good Manufacturing Practices (GMP), GxP requirements, and global regulatory frameworks such as FDA and EMA guidelines. The review also addresses key challenges associated with AI adoption, including data quality and scarcity, algorithmic bias, system interpretability, cybersecurity risks, infrastructure limitations, workforce skill gaps, and regulatory complexity. Emerging solutions such as explainable AI, digital twins, IoT integration, and human-AI collaboration are discussed as critical enablers for sustainable implementation. Overall, AI and automation represent transformative tools for modern pharmaceutical QA, offering enhanced efficiency, reliability, and compliance while supporting continuous quality improvement and accelerated time-to-market. Their responsible and validated integration is essential for ensuring patient safety and maintaining regulatory confidence in increasingly complex pharmaceutical systems.
Keywords: Pharmaceutical Quality Assurance; Artificial Intelligence; Automation; Pharma 4.0; Machine Learning; Predictive Analytics; Regulatory Compliance; Digital Twin

❖ Introduction:

Pharmaceutical Quality Assurance (QA) plays a critical role in ensuring that pharmaceutical products consistently meet established standards for quality, safety, and therapeutic efficacy. As artificial intelligence (AI) technologies are integrated into various pharmaceutical operations, it becomes essential that QA principles are rigorously upheld to maintain regulatory compliance and protect patient health. Artificial Intelligence refers to computational systems designed to emulate human cognitive functions and perform tasks that typically require human intelligence. AI is widely recognized as a technology capable of replicating complex human abilities through machine-based learning and reasoning. The conceptual foundation of AI was first introduced in 1956 during a landmark workshop organized by Marvin Minsky and John McCarthy.

Artificial intelligence in the pharmaceutical industry refers to the deployment of computational algorithms capable of performing tasks traditionally carried out by humans. Over the past five years, the incorporation of AI technologies has significantly transformed pharmaceutical research and development, reshaping the processes through which scientists design new therapeutic agents and address complex diseases. A key objective of this research is to provide industry leaders with a comprehensive understanding of the substantial biotechnological advancements enabled by AI. Artificial intelligence enables machines to replicate human-like behaviors and make logical decisions by selecting the most effective course of action. It encompasses the development of technologies capable of performing complex functions such as planning, reasoning, problem-solving, and perception. Today, AI is widely integrated across global industries, including the pharmaceutical sector, where its applications are rapidly expanding. In pharmaceuticals, AI supports a broad range of activities, including drug discovery and development, optimization of manufacturing processes, improvement of medication adherence and dosing strategies, and identification of new therapeutic uses for existing drugs.(1).

The quality of pharmaceutical products is typically established and evaluated through defined quality attributes and standards outlined in current Good Manufacturing Practices (cGMP), pharmacopoeial monographs, and regulatory guidelines. To ensure that finished pharmaceutical products comply with these standards, Quality Assurance (QA) units must implement structured and systematic activities, including warehouse oversight, in-process quality assessments, and visual inspection, among other QA functions.

As a key component of the Fourth Industrial Revolution, artificial intelligence (AI) is profoundly transforming industrial operations, including those within pharmaceutical manufacturing. AI, a multidisciplinary field, enables machines to emulate human cognitive capabilities such as learning, reasoning, and problem-solving to perform tasks traditionally dependent on human intelligence.

AI-driven automated visual inspection systems facilitate real-time monitoring and enhance defect detection, surpassing the performance of conventional visual assessments, which are often influenced by operator variability and environmental conditions. Additionally, pharmaceutical manufacturers increasingly leverage predictive analytics, allowing AI systems to analyze historical datasets to anticipate potential quality risks, detect anomalies, and issue early warnings. This predictive capability enables timely implementation of corrective and preventive measures before quality deviations manifest.

Classification of Artificial Intelligence

Artificial Narrow Intelligence (ANI): ANI refers to AI systems designed to perform a specific, well-defined task with high proficiency such as facial recognition, autonomous driving, or strategic gameplay. These systems operate within restricted functional boundaries and do not possess the cognitive versatility characteristic of human intelligence.

Artificial General Intelligence (AGI): AGI represents a level of intelligence comparable to that of humans, with the capacity to understand, learn, and apply knowledge across diverse domains. Such systems can adapt to new situations, perform multiple tasks, and solve complex problems using generalized reasoning abilities.

Artificial Superintelligence (ASI): ASI denotes a hypothetical form of intelligence that surpasses human cognitive capabilities across all fields, including scientific analysis, creative arts, and strategic decision-making. ASI would be capable of achieving outcomes far beyond the limits of human performance.

Synergy Between Artificial Intelligence (AI) and Quality Assurance (QA):

The integration of Artificial Intelligence (AI) with Quality Assurance (QA) in the pharmaceutical sector creates a highly effective framework that strengthens the accuracy, reliability, and efficiency of drug-development, manufacturing, and regulatory processes. This synergy enhances quality oversight across the product lifecycle in several key ways:

1. **Advanced Data Processing and Analysis:**

High-Volume Data Management: Pharmaceutical QA relies on extensive datasets generated from clinical studies, manufacturing operations, and post-marketing surveillance. AI especially machine learning (ML) algorithms can rapidly process and interpret these large datasets, identifying subtle trends and potential quality concerns that may be overlooked through manual evaluation.

Real-Time Surveillance: AI-enabled systems allow continuous monitoring of process parameters, enabling immediate detection of deviations from established standards. Early identification of abnormalities facilitates prompt corrective measures, reducing the probability of defects.

2. **Predictive Quality Assurance:**

Predictive Analytics: AI can evaluate historical manufacturing and equipment data to anticipate failures or deviations in product quality before they occur. This proactive approach transitions QA from a reactive model to a preventive one.

Early Warning Mechanisms: AI-driven platforms can generate alerts for QA teams by recognizing patterns associated with potential batch failures, environmental fluctuations, or minor variations, thereby enhancing risk mitigation.

3. **Automated Quality Control**

Automated Inspection and Testing: AI can perform automated visual inspections and detect micro-level defects with greater precision than human inspectors. This ensures uniformity and reliability in product quality across multiple batches.

Process Optimization: AI-supported systems can dynamically optimize manufacturing parameters to maintain processes within regulatory limits, reduce variability, and improve batch consistency.

4. Enhanced Decision-Making Support

Data-Driven Decision Systems: AI provides QA teams with sophisticated analytical tools capable of evaluating complex datasets and generating evidence-based recommendations related to product release, risk control, and regulatory compliance.

Risk-Based QA Approaches: AI can rank potential risks and guide resource allocation toward high-risk areas, improving compliance efficiency and strengthening overall quality management.

5. Regulatory and Compliance Support

Automated Compliance Verification: AI facilitates compliance with Good Manufacturing Practices (GMP) by automatically reviewing documentation, detecting deviations, and ensuring that all production steps align with regulatory standards.

Audit Preparedness: AI systems maintain organized, searchable audit trails, improving documentation accuracy and reducing manual workload during regulatory inspections.

6. Minimization of Human Error

Automation of Routine Tasks: By automating repetitive activities such as data entry, documentation, and routine QC checks, AI significantly reduces the likelihood of human error.

Improved Consistency: AI-driven QA processes remain unaffected by fatigue or subjective bias, ensuring consistent and accurate quality assessments.

7. Accelerated Time-to-Market

Increased Efficiency: AI's ability to rapidly evaluate data, predict deviations, and automate QA functions shortens review timelines, enabling faster product releases without compromising safety or efficacy.

8. Cost Optimization

Reduced Operational Costs: Automation lowers labor dependency and enhances accuracy, ultimately reducing QA-related expenses.

Lower Recall Rates: By identifying potential quality failures earlier and tightening process controls, AI helps minimize the financial burden of product recalls and quality defects.

Barriers and Future Directions for AI Integration in Quality Assurance:

One of the principal challenges hindering the integration of artificial intelligence into quality assurance processes is the shortage of personnel with adequate expertise in AI-related technologies. Addressing this skills gap will require the establishment of structured AI training programmes developed through partnerships among universities, digital technology providers, and research institutions. Similar collaborative initiatives have already been implemented in other countries. For instance, India's Ministry of Electronics and Information Technology (MeitY), in conjunction with the National Association of Software and Service Companies (NASSCOM), introduced the Future Skills Prime (FS Prime) programme to enhance workforce competence in AI and other emerging technologies.(2)

Increasing awareness of the potential benefits of artificial intelligence within this sector can be facilitated through specialized workshops and government-driven sensitization initiatives, which have shown effectiveness in other regions. For example, the European Medicines Agency (EMA) has undertaken studies illustrating the contribution of AI to enhancing pharmaceutical industry operations, thereby supporting stakeholders in recognizing its value.(3)

Stages of AI Adoption in the Supply Chain

Selection: The first stage involves identifying the most suitable Clinical Decision Support System (CDSS) that aligns with the intended application and integrates seamlessly with existing clinical workflows. This includes evaluating the system's compatibility with the "five rights," performance criteria, and user acceptance.

Acceptance Testing: At this stage, the CDSS is rigorously assessed to ensure compliance with safety, security, and privacy requirements applicable to medical devices. Testing covers typical error conditions, exceptions, and unexpected operational scenarios.

Commissioning: Before clinical deployment, the CDSS is optimized for local use potentially through customization and evaluated for safety, accuracy, and performance within the specific clinical environment.

Implementation: This step involves the full-scale rollout of the CDSS, transitioning from the previous workflow to the newly integrated system. Training of end users and effective management of their expectations are critical components of this phase.

Quality Assurance: Ongoing QA ensures that the CDSS continues to perform reliably and remains appropriate for its intended purpose. This includes monitoring software updates, contextual changes, and internal or external factors that may influence performance.

Role of Artificial Intelligence in Quality Management:

1. AI significantly enhances modern quality management systems by automating key quality control functions. Through AI-driven data acquisition, processing, and analytical tools, organizations can streamline inspection, testing, and other critical QA activities.(1)

2.AI algorithms possess the ability to rapidly evaluate large datasets, enabling prompt and accurate decision-making while reducing the need for manual intervention. This capability strengthens predictive analytics within quality assurance frameworks. By leveraging historical data and machine learning models, organizations can detect early indicators of defects or potential deviations in quality processes.

3.This proactive assessment facilitates the implementation of preventive measures, thereby minimizing the occurrence of quality-related issues. AI-based monitoring systems and sensor networks further support real-time quality surveillance. These systems continuously capture quality metrics, identify abnormal patterns, and contribute to ongoing improvement efforts.(4)

4.AI's adaptive algorithms can recognize complex trends and irregularities that may be difficult for human inspectors to detect, allowing timely resolution of quality challenges and promoting improved product consistency and customer satisfaction.

Advantages of Artificial Intelligence in Quality Management:

1. Greater Accuracy and Reliability: Through automation and the application of advanced algorithms, AI minimizes human error in quality management processes. AI systems are capable of detecting and analyzing defects with high precision, resulting in more consistent and reliable quality outcomes.(5)

2. Improved Efficiency and Productivity: AI-driven automation and data analysis significantly enhance operational efficiency. By reducing reliance on manual activities, organizations can accelerate quality evaluations and streamline processes, leading to reduced labor demands, cost savings, and optimized resource utilization. AI-based insights also support stronger decision-making by identifying areas requiring improvement and optimizing overall quality workflows.(6)

Advancements in Medical Device Quality and Compliance: In the medical device industry, precision is critical. AI transforms manufacturing processes by analyzing extensive datasets to support design, prototyping, production, and post-market surveillance. AI-powered Quality Management Systems (QMS) ensure adherence to stringent regulatory standards throughout all stages of the product lifecycle. Regulatory bodies such as the FDA require strict compliance from manufacturers. AI not only facilitates adherence to these requirements but also enhances the speed and accuracy of the regulatory approval process. By integrating AI, medical device companies can significantly reduce time-to-market without compromising safety, efficacy, or quality. (6)

Advantages of Artificial Intelligence Technology:

Artificial intelligence (AI) offers numerous benefits across various sectors due to its capability to perform complex tasks with high accuracy and efficiency. The major advantages include:

1. Error Reduction:

AI systems significantly minimize human errors and enhance precision. Intelligent robots, built with durable materials capable of withstanding harsh environments, are often deployed for space exploration where human presence is difficult or risky.

2. Support in Difficult Exploration:
AI plays an essential role in industries such as mining and fuel exploration, where conditions may be hazardous or inaccessible to humans. AI-driven systems can also explore deep-sea environments, compensating for limitations caused by human error.
3. Applications in Daily Life:
AI contributes to everyday activities through tools such as GPS for navigation and predictive text systems in mobile devices. These systems assist in anticipating user inputs and correcting typographical errors, thereby improving user experience.
4. Digital Assistants:
Many advanced organizations use AI-powered digital assistants or "avatars" to reduce the dependency on human labor. These systems make rational, emotion-free decisions, avoiding the biases and inconsistencies associated with human emotions.
5. Handling Repetitive Tasks
While humans typically perform one task at a time, AI systems can manage multiple operations simultaneously. Their parameters—such as speed and processing time—can be adjusted to suit specific requirements, enabling faster and more efficient task execution.
6. Medical Applications
AI enhances clinical decision-making by analyzing patient conditions, predicting adverse drug reactions, and supporting diagnosis. Medical trainees also benefit from AI-based surgical simulators (e.g., gastrointestinal, cardiac, or neurological simulations) to gain hands-on experience in a risk-free environment.
7. Continuous Operation
Unlike humans, who require rest, AI-driven machines can operate continuously for extended periods without fatigue, confusion, or loss of productivity.
8. Acceleration of Technological Development
AI supports the creation of advanced computational models and contributes to drug discovery and drug-delivery system development. Its widespread use in innovation drives rapid technological growth.
9. Reduced Risk in Hazardous Environments
In high-risk areas such as firefighting or disaster zones, AI-based robotic systems can take the place of human workers. Even if damaged, these machines can be repaired, minimizing human injury or loss.
10. Assistance Across Age Groups
AI systems can function as 24/7 support tools for children, elderly individuals, or people needing constant guidance. They also serve as educational tools for teaching and learning.
11. Expanded Functional Capabilities
Machines are not constrained by emotional or psychological limitations. They can perform complex tasks efficiently and produce results with higher accuracy and consistency compared to humans.

Disadvantages of Artificial Intelligence Technology

Despite its advancements, AI technology also presents several challenges and limitations:
1. High Cost
Developing AI systems requires substantial financial investment. Designing, maintaining, and repairing sophisticated AI machines is costly. Frequent software updates and reinstallation processes further increase expenses and time requirements.
2. Inability to Replicate Human Judgment
Although AI-based robots can mimic human thinking to some extent, they lack emotional intelligence and intuition. In unfamiliar or unexpected situations, they may fail to make correct decisions, potentially resulting in inaccurate outputs.
3. Lack of Learning Through Experience
Humans improve their skills over time through experience. In contrast, AI systems do not inherently learn or evolve unless explicitly programmed or updated. They cannot evaluate human qualities such as diligence or work ethic

4. Absence of Original Creativity
AI lacks intrinsic creativity, emotional depth, and sensory perception. Humans can imagine, innovate, and think abstractly—abilities that AI cannot replicate without predefined data or algorithms.
5. Risk of Unemployment
Extensive implementation of AI across industries may lead to workforce displacement, reducing employment opportunities. Overdependence on automated systems may also diminish human creativity, motivation, and skill development. (5)

AI Model Training and Fine-Tuning:
The integration of artificial intelligence (AI) into quality assurance (QA) processes is challenged primarily by the presence of bias in training datasets. AI systems can inherit and amplify these biases, leading to inequitable or inaccurate assessment outcomes. Therefore, the utilization of diverse, representative, and real-world data sources is essential to ensure optimal model performance and to minimize systematic errors during training.

Interpretability and Transparency of AI Outputs:
Another critical challenge in adopting AI for QA is the need for transparent and interpretable outputs. Ensuring that AI-generated decisions are understandable is essential for building trust among testers and end-users. Explainable AI (XAI) frameworks play a pivotal role in this context by providing insights into the logic, context, and rationale behind AI-driven decisions. XAI enhances testing precision, supports rapid decision-making, and contributes to generating reliable and comprehensible outcomes.

Ethical Considerations in AI-Driven Quality Assurance:
AI testing raises several ethical concerns because models may develop biased behaviours due to skewed or unrepresentative training datasets. Such biases can result in discriminatory outcomes, particularly affecting vulnerable or diverse population groups. Ethical considerations are therefore central to AI QA, especially in healthcare, where inaccuracies or unintended consequences can directly compromise patient safety and erode trust in medical products. Ensuring ethical integrity during algorithm development and evaluation is crucial for maintaining product credibility.

Key Ethical Issues in AI Integration for QA and Testing-

Design and Development of Digital Health Technologies:
Given the sensitivity of health-related data, digital health systems must be designed to prioritize data protection without compromising clinical outcomes. Patient anonymity and compliance with regulatory frameworks such as HIPAA and GDPR are essential for maintaining data security and ensuring user trust.

Testing of AI-Based Systems:
AI tools improve automation and efficiency in QA, yet their decisions must remain transparent and explainable. Thorough testing is essential to validate the model's ability to justify its outputs, ensuring accountability and reliability in AI-driven testing workflows.

Human Oversight in AI Evaluation:
Achieving the full potential of AI systems requires continuous human supervision. Test protocols should incorporate human-in-the-loop approaches to prevent erroneous or harmful outcomes, particularly in diagnostic or clinical decision-support applications.

Use of ChatGPT-Like Models in Healthcare QA:
AI language models such as ChatGPT can support QA for healthcare products, but their comprehension of complex medical terminology and patient-specific language must be rigorously evaluated. Since healthcare contexts demand empathy and accuracy, these models must be assessed for reliability, consistency, and potential misuse of patient data.

Factors Influencing FDA Approval of AI-Enabled Medical Devices:

- **Regulatory Complexity and Compliance Burden:**

One of the most significant challenges in QA for medical technologies is navigating the complex and continuously evolving regulatory landscape. Standards established by bodies such as HIPAA, the FDA, and the CMS require organizations to maintain stringent compliance related to data protection, clinical safety, software interoperability, and overall system reliability. Noncompliance can lead to legal ramifications, loss of accreditation, and reputational damage. Additionally, inconsistencies between international regulatory standards further complicate compliance for global healthcare organizations.

- **Technological Advancement and System Integration:**

Rapid technological innovation—particularly in areas such as Electronic Health Records (EHRs), telemedicine, and AI—creates both opportunities and challenges. Integrating advanced digital systems into existing healthcare frameworks requires robust QA processes to ensure system compatibility, performance reliability, and data protection.

- **Patient Safety and Risk Management:**

Patient safety remains a central pillar of healthcare QA. Despite technological progress, substantial risks persist, including healthcare-associated infections, medication errors, and failures of medical devices. Effective risk management requires proactive identification, assessment, and mitigation of these hazards through strong QA strategies and continuous performance monitoring. (6)

1. **AI-Driven Quality Assurance Challenges:**

AI-driven Quality Assurance (AI-QA) introduces many exciting opportunities, but also brings several challenges related to data, algorithms, infrastructure, and organizational adoption. One of the most critical areas of complexity is data, which forms the foundation of all AI systems. Below is a detailed review of the data-related challenges in AI-driven QA, including their causes, impacts, and potential solutions.

1. Data-Related Challenges in AI-QA:

Data fuels AI models. In QA, effective AI relies on high-quality input such as defect reports, user behavior logs, test execution records, system performance metrics, and production data. When this data is insufficient, inconsistent, or poorly managed, AI-QA systems struggle to produce reliable outputs.

Key challenges include:

i. Data quality issues
ii. Data labeling difficulties
iii. Data fragmentation and silos
iv. Privacy and compliance restrictions
v. Lack of real-world or edge-case scenarios
vi. Below is a detailed explanation of the first major challenge.

2. Data Scarcity:

Description: AI models require large volumes of historical and representative data to learn meaningful patterns. In Quality Assurance, this includes:

i. Defect logs
ii. Regression test results
iii. User behavior analytics
iv. Performance test outcomes
v. Code change histories
vi. Production incidents
vii. Test coverage data

However, many organizations—especially those dealing with new products, legacy systems, or niche domains—lack sufficient data for effective AI model training.

Common Causes of Data Scarcity-

1. New Projects: Early development phases lack historical defect or test data.
2. Limited Test Automation: Manual testing produces fewer structured and reusable datasets.

3. Niche or Customized Systems: Unique applications do not have comparable datasets available externally.
4. Siloed Tools: Data spread across Jira, TestRail, spreadsheets, and CI/CD tools makes consolidation difficult.
5. Incomplete Documentation: Missing test cases, inconsistent defect descriptions, or unlogged results reduce usable data.

Impact on AI-QA

- Low prediction accuracy (e.g., defect prediction, flaky test detection).
- Poor test generation or prioritization due to insufficient behavioral patterns.
- Bias and overfitting when models rely on too few examples.
- Delayed AI adoption because training cycles require more data preparation and manual oversight.
- Limited automation as AI cannot generalize well from small datasets.

Potential Solutions

1. Synthetic Data Generation: Use generative AI to create artificial test data, defect logs, or user interaction patterns.Helps replicate rare or edge-case scenarios.
2. Transfer Learning & Pretrained Model: Start with a model trained on industry-wide QA datasets and fine-tune it using limited internal data.
3. Data Augmentation Techniques: Expand datasets by transforming existing inputs (e.g., perturbing logs, modifying test parameters).
4. Unified Data Platforms: Integrate tools (Jira, Jenkins, Git, Test Management Systems) to consolidate and centralize QA data.
5. Automation to Increase Data Volume: Introduce automated test execution to generate more consistent and structured data logs.
6. Crowdsourcing / Cross-Project Data Sharing: For organizations with multiple products, sharing anonymized QA data across teams improves dataset richness.
7. Better Logging and Documentation Practices: Improve defect descriptions, maintain thorough test results, and enforce proper logging standards.

❖ **Challenges in the Adoption of Artificial Intelligence in the Pharmaceutical Sector:**

Despite the transformative potential of artificial intelligence (AI) within the pharmaceutical industry, its implementation is hindered by multiple structural, technical, regulatory, and organizational barriers.

A. Limited Technical Familiarity:

AI remains a relatively novel and complex technological domain, and many pharmaceutical organizations lack adequate understanding of its mechanisms. This unfamiliarity contributes to perceptions of AI as a “black-box” system, thereby limiting trust and slowing adoption.

B. Insufficient Information Technology Infrastructure:

Effective integration of AI into pharmaceutical operations requires substantial upgrades to existing digital platforms and IT infrastructure. Many organizations are unable to deploy AI solutions without significant investment in advanced hardware, software, and data-management systems.

C. Heterogeneity and Complexity of Data Formats:

Pharmaceutical data often exist in diverse and unstructured forms, including free-text records, clinical notes, and research documentation. Standardizing, cleaning, and formatting these datasets for AI-driven analysis poses a considerable challenge during implementation.

D. Regulatory Compliance Requirements:

The adoption of Pharma 4.0 technologies involves the use of sophisticated digital tools and automated systems. Ensuring full compliance with stringent regulatory frameworks—including those governing data integrity, validation, and quality management—creates substantial operational and compliance burdens for pharmaceutical companies.

E. Data Security and Privacy Concerns:

Given the high regulatory scrutiny associated with pharmaceutical data, maintaining the confidentiality, integrity, and security of sensitive information is paramount. The deployment of AI and advanced analytics heightens concerns regarding cybersecurity, data breaches, and regulatory non-compliance.

F. Integration Challenges with Legacy Systems:

Many pharmaceutical organizations rely on outdated legacy systems that lack interoperability with modern digital technologies. Achieving seamless integration between legacy infrastructure and AI-enabled platforms requires meticulous planning, system redesign, and phased implementation.

G. Talent Acquisition and Retention:

The transition toward Pharma 4.0 demands specialized competencies in data analytics, machine learning, and AI application development. Recruiting and retaining personnel with these advanced skill sets remains a major challenge for the industry.

H. Financial Constraints:

Implementing Pharma 4.0 and AI-enabled technologies entails considerable financial investment in infrastructure, software solutions, training, and workforce development. These costs pose significant challenges, particularly for small and medium-sized pharmaceutical enterprises with limited resources. (7,8)

Opportunities for AI Incorporation in the Quality Assurance in pharma industry:

The integration of artificial intelligence (AI) into pharmaceutical quality assurance (QA) systems offers substantial potential to enhance operational performance across multiple domains, including warehousing, equipment maintenance, in-process quality control, and visual inspection activities. In warehouse environments, AI-enabled sensor networks can continuously monitor critical environmental parameters—such as temperature and humidity—to ensure optimal storage conditions for thermolabile or otherwise sensitive pharmaceutical products. Furthermore, machine-learning algorithms have demonstrated significant efficacy in identifying defect patterns and detecting operational inefficiencies. These capabilities support the improvement of product quality, facilitate data-driven decision-making, and contribute to greater overall efficiency in pharmaceutical manufacturing processes.(9)

AI-driven systems are reshaping in-process quality control and inspection activities by enabling real-time monitoring of manufacturing operations, automated detection of deviations, and consistent assurance of product quality. Through continuous acquisition and analysis of data from multiple critical control points along the production line, AI facilitates immediate identification and mitigation of process anomalies, thereby supporting a more robust and responsive quality control frame work. Consequently, manufacturers experience reductions in material waste, improved production throughput, and accelerated delivery of high-quality products, while simultaneously minimizing reliance on manual inspection procedures.

In addition, AI-enabled technologies are transforming visual inspection practices. Leveraging computer vision and deep learning methodologies, these systems autonomously detect and characterize particulate contamination and other visual defects with high precision. They are capable of processing image data at speeds and accuracy levels that surpass those achievable through human inspection, thereby enhancing the reliability and efficiency of visual quality assessments.(10)

Automation in Modern Pharmaceutical Quality Assurance:

The pharmaceutical industry is governed

by strict quality assurance (QA) processes designed to verify the safety, efficacy, and quality of pharmaceutical goods. These procedures are necessary to maintain public trust in therapeutic interventions and to comply with regulatory criteria set by organizations like the World Health Organization (WHO), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA). Conventional analytical methods, batch-based quality testing, and manual inspection have always been the mainstays of QA procedures. Despite their effectiveness, these approaches are labor-intensive, time-consuming, and prone to human error.(11,12)

1. Integration of Automation into Quality Assurance Protocols in the Pharmaceutical Sector:

The combination of automation technologies encompassing robotic systems, artificial intelligence (AI), and advanced analytical platforms has produced a paradigm shift in pharmaceutical quality assurance (QA). These advances have considerably boosted the accuracy, scalability, productivity, and operational efficiency of QA procedures. Automation provides near-real-time monitoring and thorough data interrogation, so enabling continuous oversight and timely intervention. Additionally, it greatly bolsters compliance with changing regulatory frameworks by providing strict documentation trails and maintaining traceability throughout QA procedures.(13)

2. From Manual to Automated Quality Assurance:

The concept of quality, which encompasses being fit for purpose, meeting requirements, and striving for excellence, has become increasingly important over the past century. It all started in the 1920s, when American industries began adopting scientific management principles, laying the groundwork for modern quality management. However, this approach had its drawbacks by separating planning from execution, workers felt disconnected from decision-making processes, leading to growing dissatisfaction. Fast forward to the second half of the 20th century, and automation started to transform the pharmaceutical quality control landscape. Advances in technology, such as improved instrumentation and computing power, enabled the development of automated systems for tasks like testing the dissolution of substances, analyzing chemical compositions, and counting microorganisms. These automated systems brought a new level of precision and consistency to quality assessments, and significantly sped up the process, allowing businesses to make faster, more informed decisions about production and product releases.(14)

3. Leveraging Automation for Precision and Compliance in QA & QC:

The pharmaceutical industry, like many others, has witnessed unprecedented growth thanks to the power of automation. By harnessing the potential of machines and robotics, companies can efficiently complete repetitive yet crucial tasks, freeing up human resources for more strategic and creative work. Over the past few decades, automation has become increasingly prevalent, driven in part by the escalating complexity of regulatory requirements. As these requirements continue to evolve and tighten, automation has emerged as a vital tool for ensuring compliance and staying ahead of the curve. This shift underscores the importance of equipping current and future professionals with the skills to navigate emerging technologies and thrive in a rapidly changing landscape.

Key aspects of automation in quality assurance and quality control include:

- Implementing risk-based approaches to automate quality management

- Utilizing real-time monitoring and process control through Process Analytical Technology (PAT)
- Reducing errors through automated process control systems
- Applying scientific risk-based methods to enhance pharmaceutical quality
- Establishing a robust Quality Management System (QMS) for automated pharmaceutical manufacturing

This version aims to preserve the original meaning while using more dynamic language and a persuasive tone to convey the importance of automation in the pharmaceutical industry.

4. Key Advantages of Automation:

Enhancing Quality, Efficiency, and Compliance: Automation has become an integral part of quality assurance, offering numerous benefits that enhance efficiency and effectiveness. By reducing manual intervention, automation minimizes errors, ensures consistency, and accelerates processes.

Quality and Safety: Improving product quality and ensuring patient safety are critical objectives in the pharmaceutical industry. Digital transformation, focused on enhancing Quality Management Systems (QMS) and maintaining regulatory compliance, plays a vital role in achieving these goals. digitalization helps streamline quality management procedures, reducing human error and ensuring consistent adherence to standards and best practices.(15)

Tracking Products Technologies: with Advanced Automation enables robust tracking mechanisms for pharmaceutical products by integrating advanced technologies such as Electronic Batch Records (EBR) and Radio Frequency Identification (RFID). These systems allow for real-time monitoring of production and supply chain processes, ensuring comprehensive traceability from raw materials to the final product. EBR provides a digital, error-proof record of each manufacturing stage, while RFID tags facilitate precise tracking of products across storage and distribution networks. Together, these technologies enhance transparency and accountability, helping pharmaceutical companies maintain compliance with regulatory standards and quickly address potential issues.(7,8,16)

Streamlining Manufacturing Development Processes: Automation significantly enhances efficiency in pharmaceutical manufacturing and development by simplifying and streamlining complex workflows. Automated systems optimize time and resource utilization by ensuring consistent and repeatable operations, reducing manual interventions, the integration of automation helps meet the growing demand for medicines and ensures compliance with stringent regulatory requirements, positioning companies to respond effectively to both market needs and global health challenges (7).

Enhancing Accuracy and Precision: The adoption of automation in processes such as packaging, weighing, and blending has revolutionized pharmaceutical manufacturing by significantly reducing the risk of human errors. this increased accuracy directly contributes to patient safety, as medications are produced to meet exact specifications, ensuring proper dosage and efficacy. Automation also supports compliance with regulatory standards by maintaining detailed records of each step in the process, further solidifying its role in safeguarding product quality and consumer health Automation significantly enhances efficiency in pharmaceutical manufacturing and development by simplifying and streamlining complex workflows. Automated systems optimize time and resource utilization by ensuring consistent and repeatable operations, reducing manual interventions, the integration of automation helps meet the growing demand for medicines and ensures compliance with stringent regulatory requirements, positioning companies to

respond effectively to both market needs and global health challenges. (7)

❖ Role of AI in Pharmaceutical Quality Assurance -

Predictive Analytics: By analyzing past data from manufacturing processes, equipment performance, and quality control tests, AI algorithms can be trained to anticipate possible failures or deviations in product quality before they happen (4), allowing for proactive risk management (15). This reduces testing time and expenses, improves overall efficiency, prevents faults or anomalies in medication production, and helps prioritize data and allocate resources more effectively (16).

Image Recognition & Computer Vision:

Image Recognition: Deep learning is very useful for quality assurance applications involving visual inspections since it performs exceptionally well in picture recognition tasks. For defect identification and picture classification, convolutional neural networks (CNNs) are frequently employed (17). Images from manufacturing lines, such as tablet inspections, can be analyzed by this AI program to find flaws like fractures, discolouration, or improper sizes (4), as well as packing mistakes or contamination that human inspectors could overlook (18). By reducing human error and using operational data to obtain strategic insights, this improves productivity, accuracy, and precision over manual inspections (4,19).

Computer Vision: AI-powered computer vision systems employ sophisticated image-processing algorithms and machine learning methods to evaluate visual data collected through cameras or sensors (20). These systems can examine and interpret visual inputs by scanning images of pharmaceuticals (21), labels, and packaging to detect defects or irregularities in manufacturing processes, thereby reducing or eliminating the need for manual inspection (22,23). For quality assurance teams, this results in greater precision during visual regression testing, improved and partially or fully automated QA procedures, and enhanced overall accuracy and consistency. Computer vision is also utilized to confirm that labels are properly applied and display correct information, including verifying text accuracy, barcode readability, and compliance with regulatory standards.

- **Enhanced Computer Vision Techniques:**

3D Vision and Imaging: Advances in 3D imaging and analytical technologies are making inspections more thorough. Methods such as structured light scanning and time-of-flight cameras facilitate precise assessment of product dimensions and surface characteristics (24).

Real-Time Video Analytics: The capability to process and analyze video streams instantaneously is becoming increasingly achievable. This enables continuous oversight of production lines, allowing defects and anomalies to be identified and addressed as soon as they occur (17).

Natural Language Processing (NLP): NLP is widely applied to analyze unstructured information from various sources, such as clinical trial data (15), product descriptions, maintenance records (20), regulatory files, and customer reviews, to extract key insights related to product quality and safety issues (18). It also facilitates the automated examination of regulatory reports and documents, ensuring compliance with the standards set by authorities like the FDA and EMA (4). In the field of Quality Assurance (QA), artificial intelligence (AI) uses NLP to understand customer needs expressed in everyday language and convert them into test scenarios or automated scripts (21). By leveraging AI algorithms to analyze textual data, companies can uncover potential problems that require attention, thereby improving QA processes and supporting faster, evidence-based decision-making (18).

Root Cause Analysis: AI tools assist in determining the underlying causes of recurring quality problems in both development and manufacturing processes (4,25) by analyzing extensive historical data from production and testing activities (15). This analysis supports process optimization and enhances product consistency and quality (15). By pinpointing these root causes, QA teams can apply focused preventive strategies to minimize the likelihood of future defects (16,26,27).

Pattern Recognition: Unsupervised learning plays a crucial role in manufacturing quality assurance when labeled data is limited or unavailable. This approach, which encompasses clustering algorithms such as K-Means and DBSCAN (Density-Based Spatial Clustering of Applications with Noise) along with association rule learning, is especially effective for identifying patterns, detecting faults, and analyzing process improvements (28).

Anomaly Detection: Machine learning algorithms are employed to identify anomalies in real time, such as minor variations in chemical composition or environmental parameters, as well as deviations within batch records, highlighting potential noncompliance issues for prompt correction. Although these changes may initially go unnoticed, they can gradually impact product quality. Anomaly detection models utilize data from multiple sensors and devices to uncover patterns indicating abnormal behavior (4). Supervised learning is the most commonly applied approach in manufacturing QA, owing to its effectiveness with labeled datasets (28). Early identification of anomalies enables swift corrective measures before they evolve into major quality problems or production delays, thereby preserving product integrity and ensuring adherence to regulatory standards (18).

❖ Role of Automation in Pharmaceutical Quality Assurance

Introduction to Automation in QA: Automation refers to a collection of technologies that enable machines, equipment, and systems to perform both physical and cognitive tasks within the pharmaceutical industry (29), minimizing the need for human intervention and delivering performance levels that surpass manual operations (29,30). The incorporation of automation into QA processes has transformed the pharmaceutical sector. Through the use of robotics, artificial intelligence (AI), and advanced analytics platforms, organizations aim to enhance precision, scalability, productivity, and efficiency within their quality assurance frameworks. Moreover, automation supports real-time monitoring and data analysis while ensuring compliance with continuously evolving regulatory standards through comprehensive documentation and traceability (31).

Robotic Process Automation (RPA): RPA is a technology that employs software robots, or “bots,” to automate routine and repetitive administrative tasks (32), including data entry, inventory management, batch processing, document handling, and compliance reporting, thereby reducing errors and enhancing operational efficiency (33).

Robotic Process Automation (RPA) improves operational efficiency in the pharmaceutical sector by streamlining data entry and validation, managing inventory based on demand trends, and automating data collection and reporting to maintain regulatory compliance. Additionally, it aids in quality assurance by checking product labeling, batch uniformity, and packaging accuracy, ensuring conformity with regulatory requirements (32).

Automated Documentation: Automated documentation systems leverage artificial intelligence (AI) to gather and store data from multiple sources, including manual entries, production equipment, and laboratory instruments (34). Natural Language Processing (NLP) enables automated review of regulatory documents, ensuring adherence to standards set by agencies such as the FDA or EMA (4). These systems enhance data integrity, reduce the likelihood of human error, and provide a transparent audit trail to support regulatory compliance (34).

Electronic Batch Records (EBR): Electronic batch records are digital platforms that replace traditional paper-based batch records for documenting production activities, process parameters, and product specifications (35), while RFID tags enable accurate tracking of products throughout storage and distribution networks (31). EBR systems maintain data integrity and support regulatory compliance by providing electronic signatures, audit trails, and real-time data collection (35). By implementing automated EBR systems, manufacturers can enhance traceability, streamline batch review processes, and achieve faster and more reliable accountability in pharmaceutical production (31).

Supervisory Control and Data Acquisition (SCADA): SCADA is a system that integrates both software and hardware components (36). It serves as a centralized platform for overseeing an entire plant, designed to generate reports and analyze trends from the data recorded within the system. Key features of SCADA include alarms, trend analysis, historical data, and process pop-ups, making it widely used in the automation industry. In this system, reactor process sensors are continuously monitored in real time, with the data stored in a dedicated database on a personal computer. The SCADA system implemented here uses VIJEO CITEC 2015, version 7.50 software (37).

Manufacturing Execution System (MES): MES, or Manufacturing Execution System, is primarily used to collect and maintain records of the production process and can also help optimize manufacturing operations(36). In pharmaceutical manufacturing, MES acts as the central platform for managing batch production, electronic signatures, and data integrity, ensuring compliance with regulations such as 21 CFR Part 11, 21 CFR Parts 210 and 211, ICH Q7, and EudraLex Volume 4 Annex 11. Siemens Opcenter MES and Rockwell FactoryTalk PharmaSuite are highlighted as industry-leading platforms due to their comprehensive capabilities designed for the life sciences sector. These systems streamline production workflows, support regulatory compliance, and integrate effectively with both shop-floor automation and enterprise systems(38).

Robotics and Machinery:

Robotic Arm: Robotic arms are versatile tools used in the pharmaceutical industry for tasks such as assembling, labeling, and picking and packing. These robots enhance productivity and quality control in pharmaceutical manufacturing by managing sensitive materials and performing repetitive tasks with high precision and efficiency. Currently, processes like nuclear magnetic resonance (NMR) and high-performance liquid chromatography (HPLC) can have their sample preparation automated using robotic arms (35).

Automated Testing and Inspection:

Sample Testing and Analysis Robots: These robotic systems automate the collection and analysis of samples from drug production batches. Equipped with advanced sensors and analytical instruments, they can rapidly and accurately assess quality parameters such as purity, potency, and stability, ensuring that products comply with stringent regulatory standards (39).

Automated Visual Inspection: Machine learning models are utilized to perform automated visual inspections of pharmaceutical products. Leveraging image recognition technology, these systems can identify defects, including packaging errors or contamination that might be overlooked by human inspectors.

This automation improves the speed and accuracy of quality checks, reducing the likelihood of defective products reaching consumers. Implementing automated visual inspection enhances quality assurance and boosts operational efficiency in manufacturing, ensuring higher levels of product integrity (18).

Laboratory Automation Systems:

Laboratory Automation: Robotic platforms are employed in laboratory automation systems to optimize a range of lab activities, including testing, analysis, and sample preparation (35). Robots can efficiently automate liquid handling processes. These systems enhance pharmaceutical research and development laboratories by increasing throughput, consistency, and accuracy (40).

Laboratory Information Management Systems (LIMS): Laboratory Information Management Systems are software-based platforms designed to support and manage modern laboratory operations. Core features of LIMS include workflow management, data tracking, data exchange interfaces, assay data management, data mining, data analysis, and integration with electronic laboratory notebooks (ELNs), among others (41).

IoT and Sensor Integration:

IoT Integration: Real-time monitoring and automation at the facility level provide timely insights into production processes. IoT sensors, when integrated with AI systems, allow continuous, real-time tracking of raw materials, equipment, and production conditions, while maintaining precise records for each batch at every production stage. This ensures full traceability, supports regulatory compliance, and enables the detection of quality issues even after products have left the manufacturing site (42).

Sensor Integration: Combining AI with sensor-based monitoring in equipment such as pumps, reactors, and filtration systems enables the prediction of mechanical failures or performance decline before they impact quality control. This proactive approach helps minimize production disruptions (15).

Regulatory and Compliance Automation:

Regulatory Compliance Automation: Automation technologies, including NLP (20) and AI, streamline documentation, enable accurate records management, manage audit trails, and automate reporting processes, ensuring compliance with FDA, EMA, and GMP guidelines. This reduces compliance-related risks and eases the workload of QA teams. Additionally, automated production systems continuously monitor environmental conditions, batch records, and other critical parameters in real time to maintain adherence to regulatory requirements (40).

Automated Audit Trail Review: Automated audit trail review uses RPA robots to extract, analyze, and verify electronic records against predefined compliance standards. The system performs timestamp validation, categorizes user actions, and detects patterns to identify potential anomalies or suspicious modifications. When integrated with AI models, it provides context-aware interpretation of actions, prioritizes events for human review, and generates summary reports to support regulatory audits (43).

Real-Time Data Monitoring: Automation systems enable continuous monitoring of manufacturing processes, allowing for the detection of deviations in key parameters such as temperature, humidity, and equipment performance. Real-time analytics support QA teams in making faster decisions and ensuring consistent product quality throughout production (15).

Automated Document Review: This system supports the creation of regulatory documents as well as the review and summarization of batch records and standard operating procedures (SOPs). AI models automate the extraction of critical data from manufacturing records and carry out precise data entry tasks. Utilizing AI-driven systems enables teams to efficiently review batch records, identify inconsistencies, and accelerate regulatory approval processes(44).

Automated Report Generation and Submission Workflows: RPA bots extract data from multiple record systems, including SAP and MasterControl, to automatically prepopulate regulatory reports. Logic-based templates reduced the assembly time for FDA Form 483 responses from 18 to 22 minutes per filing. Version control compliance is maintained via SharePoint with mandatory metadata tagging (document type, product code, effective date), reducing documentation errors by 91%. Bots also perform automatic ICH eCTD structure validation, rejecting filings with missing sections in 98.7% of test cases (43).

Data Integrity: Data integrity is a vital component of automated quality assurance in the pharmaceutical industry, ensuring that data collected, stored, and analyzed remains accurate, complete, and secure throughout its lifecycle. Regulatory authorities closely evaluate data integrity during quality assessments, emphasizing compliance with 21 CFR Part 11, which requires automated systems to not only record data but also track any updates or modifications. Adherence to ALCOA principles—Attributable, Legible, Contemporaneous, Original, and Accurate is critical for maintaining confidence in digital records(31). While CFR-compliant technologies help safeguard data integrity, it is the responsibility of QA management to ensure that data access is restricted to authorized personnel(29). The widespread adoption of digital data collection technologies reduces the need for traditional paperwork, necessitating training for QA teams in digital systems. By following data integrity best practices, the pharmaceutical industry can strengthen regulatory compliance, reduce errors, and ensure the reliability of digital quality assurance processes (45).

- ❖ **AI & automation in regulatory compliance:**

Regulators are primarily concerned about the safe and effective performance of AI-enabled technologies and must carefully evaluate whether their performance meets clear regulatory standards. Artificial intelligence (AI) is artificially stimulating intelligently (or rationally) behaving entities for making decisions or dealing with certain tasks. AI applications in intelligent agents currently include expert systems, natural language, and speech recognition and synthesis, and vision. Though it is hyped that AI could substitute for human intelligent diagnosis and clinical treatment, these algorithms may never replace clinicians because they are not living creatures that have the power of intelligence; "prescriptive" AI methods lead to difficult-to-interpret results

Regulatory compliance is arguably the most critical aspect of medical device development; it defines the framework by which regulatory bodies ensure both patient safety and product efficacy. Both compliance and quality assurance (QA) are often overlooked in research and development (R&D), due to the overwhelming nature of inventing a new technology. Compliance and quality objectives must be defined early in the process, and should be updated over the course of a project's timelines. Compliance efforts exist at constantly changing targets as regulatory agencies are very active in the medical devices space. AI is being applied to areas such as clinical-decision-making and precision medicine, where early diagnoses or targeted therapies become feasible given large-scale clinical data.

AI-driven clinical research and development of medical devices offer the possibility to think about regulatory conformance at the data level. Therefore, a data-driven approach to control regulatory compliance on the protocol, execution, and analysis of clinical trials is introduced and shown into practice. AI-driven clinical research methodologies are vital to mediate the rapidly changing landscape of AI technologies and their applications in medical device development for regulatory compliance and maintain quality assurance. AI has the potential to lead to long overdue breakthroughs in healthcare research by improving regulatory compliance, quality assurance, and data analytics, continuous advocacy is necessary to ensure that these benefits are indeed realized and that carefully thoughtout safeguards are put in place along the way(46).

Digital Validation System:

Performance-based regulation, which emphasizes measurable outcomes over prescriptive processes, aligns well with the data-driven capabilities of Industry 4.0, enabling real-time assurance of product quality and process optimization. However, this shift introduces challenges for regulators, particularly in overseeing the dynamic, data-rich environments facilitated by advanced technologies like AI and digital twins. Electronic data management systems, automated validation processes, and comprehensive audit trail functionalities ensure the accuracy, completeness, and reliability of data, meeting the stringent demands of regulatory bodies. Efforts like those by the FDA aim to adapt regulatory structures to manage data-intensive validation concepts, processes, and evolving decentralized manufacturing platforms for essential drugs (31).

The validation process within the pharmaceutical industry requires that companies have documented proof that quality and regulatory procedures are being followed during every step of the manufacturing and distribution process. Validation, all computer software and hardware required documentation to prove that processes meet standards, that proper testing of software was done, and verification through inspection and review had been conducted. Electronic system validation and a focus on specific parts of the 21 CFR Part 11 regarding just electronic records and signatures resulted in some companies spending millions of dollars trying to meet regulatory demands without establishing a reliable electronic validation system that produced adequate documentation or had the ability to adapt and accommodate new technology. An effective electronic validation system would have a way of organizing the documentation and also keeping track of the changes through audit trail and other system indicators ("System Validation for 21 CFR Compliance," n.d.). Working with pharmaceutical companies as some of their clientele, Encompass Elements needs to make sure that they adhere to regulations set forth by the FDA. They also make it a point to keep in place an electronic validation system that works and meets client needs and expectations. In addition to maintaining data integrity, pharmaceutical companies must make sure that their electronic validation system can be effective in the event of changes and/or the introduction of new technology (47).

In the field of computer system validation in the pharmaceutical industry, the well-known professional manual of the International Society for Pharmaceutical Engineering Good Automated Manufacturing Practice- ISPE GAMP5 (2008) has been developed. ISPE GAMP5 interprets regulatory requirements for the computer systems validation and aids in setting up a quality system for validating computer systems. Testing practical computer system validation against conceptual frameworks follows the suggestion that action research should have implications beyond the immediate project and that results could inform other contexts, in our case other less regulated industries. Annex 11, on the other hand, covers all activities, needed for computer system validation.

In the computer system validation and IT applications, the V-model is primarily used for the purpose of minimizing the quality risks of the computer aided system, or IT applications and for improving quality. Presented computer system validation QMS and process can provide a guideline for all companies where computer systems are important. Computer system validation ends, when the system enters the production phase (operational use). To facilitate illustration of the computer-based system validation through a concrete case, we provide key information about the selected computer system (48).

Automated audit trials: The aim of the automated audit is to identify the unregistered population, and this built-in audit is available in both study arms. An implementation strategy that can be useful for this purpose in primary care could be audit and feedback (A&F). Audit and feedback is a well-known quality intervention that, according to the last Cochrane review, leads to "small but potentially important improvements in professional practice". The extended feedback report is generated based on an automated audit that is built into the EHR of the GP(49).

Regulatory submission support:

The FDA has issued draft guidance on how to report PBPK analyses. In addition to the FDA's draft guidance, we describe suggested elements of the PBPK reports that are intended for regulatory submission. In the EMA draft guideline, special emphasis has been given to "qualification" of platform and reporting of PBPK modeling and simulation, while the FDA draft guidance focuses on the format and content of reporting PBPK analyses for regulatory submissions. The perspective of this group is well positioned to provide a "guideline" or recommendations on how to handle PBPK qualification procedures that are intended for regulatory submission and decision-making.

A framework for modeling and simulation (M&S) in regulatory reviews was proposed by Manolis et al.,41 where the degree of regulatory scrutiny, level of documentation, and the need for early dialog is proportional to the impact level of the M&S exercise in regulatory decision-making. The intended use of PBPK modeling and simulations in sup porting regulatory submissions may cover a wide range of applications in the areas of drug–drug interactions (DDI), and extrapolation across different populations such as pediatric PK analysis and absorption modeling (50).

GXP:

The document will be of assistance to all 'Good Practice' Inspectors responsible for inspecting applications in the regulated pharmaceutical sector1; hence the use of the acronym 'GxP' in the title. As technology continues its relentless advance the Expert Circle could also provide interpretation of GxP and recommend changes, if appropriate. The 1994 publication by Stokes et al provides insight into the requirements for computerised systems in GCP, GLP and GMP, together with a historical perspective on validation and international regulatory requirements. The use of validated, effective, GxP controlled computerised systems should provide enhancements in the quality assurance of regulated materials/products and associated data/information management.

The regulated users of the system have the ultimate responsibility for ensuring that documented validation evidence is available to GxP inspectors for review. GAMP Forum and PDA have provided advice and guidance in the GxP field on these matters. Validation scope should include GxP compliance criteria, ranked for product/process quality and data integrity risk criticality, should the system fail or malfunction. Risks potentially impacting on GxP compliance should be clearly identified. In order to guarantee the availability of stored data, back-up copies should be made of such data that are required to re-construct all GxP-relevant documentation (including audit trail records).

GxP Inspectors may see evidence for different forms of audit trail depending on the regulations prevailing in the intended regulated markets for the products or data. Secure, computer-generated, time-stamped audit trails to independently record GxP related actions following access to the system are used In such circumstances the controls, SOPs and records in place to ensure GxP compliance at inspection sites will need to be made available on site. Inspectors should select the GxP critical computerised systems from the information provided and consider firstly the validation evidence for the selected systems and then the routine operational controls for maintaining a valid system that is accurate and reliable (51).

GAMP:

The ISPE GAMP® Records and Data Integrity Good Practice Guide: Data Integrity by Design, Appendix S1: Artificial Intelligence: Machine Learning, identifies the life cycle of data within a ML framework, emphasizing the link to both the GAMP data life cycle and GAMP system life cycle. Wider data integrity (DI) topics are also discussed in the guide. For consistency with the GAMP® Good Practice Guide: A Risk-Based Approach to Regulated Mobile Applications, phase terminology includes project and production. This enabled automated testing and validation of the model performance during the code build cycle (52).

GAMP5 is a widely used framework for validating automated systems that establishes quality assurance practices. In 1991, in line with the changing environment of regulatory and industry initiatives, pharmaceutical specialists created the first version of GAMP. It continued to evolve and in February 2008, GAMP5wasreleased by the International Society for Pharmaceutical Engineering (ISPE). GAMP 5 principles are incorporated into several regulatory requirements, including the 21 Code of Federal Regulations Part 11 of the Food and Drug Administration (FDA). In pharmaceutical manufacturing, GAMP5 ensures the safe and compliant design, development, implementation and maintenance of automated systems. GAMP5 emphasizes regular maintenance and calibration, as well As periodic reviews and audits to ensure that everything is operating safely and compliantly (53).

Automation in manufacturing QA:

Automation began making inroads in the pharmaceutical QC/QT landscape in the latter half of the 20th century, driven by advancements in instrumentation and computing technologies. Automated systems for tasks such as dissolution testing, chromatography, and microbial enumeration offered higher precision and reproducibility compared to manual methods.

Quality Risk Management (QRM) is a risk-based, systematic, and structured approach to quality management. This involves evaluating, assessing, communicating, and controlling quality risks. This is of utmost importance to the pharmaceutical industry because product quality has a significant role to play in customer compliance, health, and safety. Quality Risk Management is an efficient method for the identification, discovery, objective evaluation, and regulation of all possible quality risks. It supports continuous processing and product quality development throughout the life cycle of the product. Modern automated systems in the pharmaceutical industry use integrated sensors to monitor process variables at every stage, ensuring operations are controlled with minimal errors. These advanced systems can detect non-compliant batches and take corrective actions, such as shutting down or rejecting the batch, with minimal human involvement. Sensors continuously gather data, which is analyzed by computers to make critical decisions, while personnel primarily ensure system functionality. A QMS provides a comprehensive framework that integrates all aspects of operations, from product development and manufacturing to distribution and post-market activities. The core objectives of a QMS include preventing quality issues, identifying and addressing deviations, and fostering continuous improvement in processes and products. Key elements of a QMS in pharmaceutical manufacturing include:

a) Formalized intentions and directions from top management regarding quality standards.

b) Documentation in the form of manuals outlining the QMS scope, processes, and procedures.

c) Detailed written instructions in the manner of Standard Operating Procedures (SOPs) to ensure consistency in performing specific functions.

d) Training and Qualification Programs to ensure personnel are adequately educated, trained, and experienced to perform their roles effectively.

e) Quality Control and Assurance: Activities such as testing, inspection, and auditing to verify compliance with quality requirements.

f) Systems for identifying, investigating, and correcting quality issues while preventing their recurrence, like Corrective and Preventive Actions (CAPA).

By adopting robust data management systems, automated quality control technologies, and real-time monitoring tools, companies can minimize errors, deviations, and contamination during technologies provide manufacturing. deeper insights These into operational processes, allowing for the early detection and resolution of potential issues. Furthermore, digitalization helps streamline quality management procedures, reducing human error and ensuring consistent adherence to standards and best practices. Revolutionized pharmaceutical manufacturing by significantly reducing the risk of human errors. Automated equipment ensures precise measurements, consistent blending ratios, and accurate packaging, all of which are critical for maintaining the integrity and quality of pharmaceutical products. Automated systems optimize time and resource utilization by ensuring consistent and repeatable operations, reducing manual interventions, and eliminating common bottlenecks in production processes. These systems enable real-time monitoring, precise control over manufacturing parameters, and the ability to rapidly adjust to changing demands or unforeseen issues(31).

6. Future Prospects of AI in Pharmaceutical Quality Assurance:

The future of AI and machine learning in pharmaceutical QA is highly promising, with numerous advancements anticipated across different operational areas:

1. Expansion of AI-Enabled Quality by Design (QbD): AI will increasingly support QbD approaches by optimizing process variables in real time and designing manufacturing workflows that inherently promote consistent product quality.

2.Integration with Advanced Analytics and IoT: The convergence of AI with the Internet of Things (IoT) will enable fully interconnected manufacturing environments. Smart sensors will provide continuous data streams for real-time quality assessment throughout the production lifecycle.

3. Development of Regulatory Frameworks for AI: Regulatory agencies such as the FDA and EMA are expected to introduce more detailed guidelines to validate, monitor, and approve AI-based QA systems, providing a clearer pathway for their compliant integration.

4.Advancements in Predictive and Prescriptive Analytics: Machine learning tools will become increasingly sophisticated, offering enhanced predictive capabilities for identifying deviations before they impact product quality. These tools will also support prescriptive actions for immediate corrective response.

5. AI in Real-Time Release Testing

(RTRT): AI will play a central role in RTRT by enabling automated, real-time evaluation of whether a drug batch meets all required quality parameters. This will reduce reliance on traditional end-point testing and accelerate batch release.

6. AI in Personalized and Biopharmaceutical Quality Assurance: As biologics, biosimilars, and gene therapies become more prevalent, AI will be essential for meeting their complex quality requirements. AI's advanced analytical capabilities will support precision QA for these highly specialized therapies(16)

Twin Digital Technology:

A digital twin (DT) is a living, intelligent and evolving model, being the virtual counterpart of a physical entity or process for practical purpose, such as monitoring and control, future prediction and planning, and conceptual design and development(54). In order to maintain a competitive edge in the market, companies strive to improve the quality and performance of their products while also minimizing downtime and maintenance costs. One of the ways to achieve this is through the use of Digital Twins (DTs), which are enabled by the fourth industrial revolution(55). In agile development, requirements continuously evolve. In other words, the quality digital twin is evaluated in every iteration to accumulate necessary quality requirements for its completion in the product backlog(54).

Visual inspection of the laboratory environment carried out with the intent of validating the flow of samples and analysts within the system, as well as providing insight into the spatial organisation of workbenches, equipment groups and data processing stations, posing as a Digital Twin of the QC laboratory(56). Digital twins hold immense promise in accelerating scientific discovery and revolutionizing industries. The use cases for digital twins are diverse and proliferating, with applications across multiple areas of science, technology, and society, and their potential is wide-reaching. Propose guidance for standardized quality assurance of digital twins in simulating product lifecycles, aiming to enhance regulatory decision-making. Digital twins, representing virtual counterparts of physical assets, processes, or systems, have emerged as a transformative force in modern industries, offering unparalleled opportunities for efficiency enhancement and innovation.

The concept of digital twins originated from the early advancements in simulation and modelling techniques. Originally designed to replicate physical systems in a digital setting, the development of digital twins has progressed from basic simulations to advanced, real-time copies that are interconnected with their physical counterparts. The origins of digital twinning may be traced back to the 1960s, when simulation technologies were used in the Apollo space programme to create replicas of spacecraft for training and testing. Digital twin" to describe the notion within the framework of Product Lifecycle Management (PLM). The evolution of digital twins, from conceptual frameworks to essential components of Industry 4.0, has been marked by important milestones and technological developments that have greatly enhanced their capabilities and range of applications. Digital twins find application primarily in predictive maintenance (PdM) and prescriptive maintenance strategies (PHM). Digital twins are used to optimise time based preventative maintenance to minimize maintenance time and unnecessary activities.

During product usage, managing and integrating vast amounts of real-time data from multiple products into a digital twin is challenging. The ability to rapidly interpret data, predict maintenance needs and execute maintenance strategies within a digital twin can become challenging to design and implement. The second challenge concerns the accuracy/ transparency of the digital twin, particularly as the physical product experiences wear and tear. Maintaining the digital twin's accuracy to reflect the physical product's rate of degradation is essential. Without standardized quality assurance procedures, validating data across many businesses is challenging. An important research obstacle in digital twins is creating techniques for evaluating data quality to guarantee the robustness of digital twins against misleading anomalies, while properly depicting significant rare occurrences. Discusses the concept of digital twin for geometry assurance, states that data quality is very important, and devises a mathematical equation to measure deviation and measurement error to consider any sensor outliers(57).

Human-AI Collaboration: Instead of replacing human QA teams, AI is expected to work collaboratively with human experts, supporting them in making informed decisions through data-driven insights (16). For example, AI can manage extensive data analysis, while human specialists are responsible for interpreting complex scenarios, particularly when AI predictions involve significant uncertainty or ambiguity (15).

❖ Conclusion :

The integration of Artificial Intelligence (AI) and automation within pharmaceutical Quality Assurance (QA) signifies a fundamental transition from traditional, reactive methodologies toward predictive and preventative frameworks. These technologies augment the precision, reproducibility, and throughput of QA workflows via real-time analytics, data-centric decision matrices, and automated feedback loops. By mitigating inter-observer variability and facilitating the early detection of process deviations, AI-driven architectures enhance product quality, ensure GxP compliance, and safeguard patient outcomes.

Nevertheless, the deployment of these systems is dependent upon overcoming technical and systemic barriers, including data silos, algorithmic bias, infrastructure scalability, and the evolving regulatory landscape. Maintaining algorithmic transparency, ethical rigor, and human-in-the-loop (HITL) oversight is imperative for establishing system validation and reliability.

In summary, the validated implementation of AI and automation—synchronized with Pharma 4.0 principles and robust regulatory frameworks—offers a high-capacity mechanism for optimizing QA cycles. This strategic adoption fosters continuous manufacturing improvements and accelerates the bench-to-bedside delivery of safe, efficacious therapeutic agents.

References:

1. Sohoni AP. AI-Driven Efficiency in Pharmaceutical Manufacturing: Enhancing Productivity, Compliance, and Decision-Making. ijmdsa [Internet]. 2025 Apr. 5 [cited 2026 Jan. 7];4(1):44-51. Available from: https://jurnal.itscience.org/index.php/ijmdsa/article/view/5715.
2. Chopra S, Meindl P. Supply chain management: strategy, planning, and operation. 6th ed. Pearson; 2016. Available from: https://www.researchgate.net/publication/247674861.
3. Chai T, Draxler RR. Root mean square error (RMSE) or mean absolute error (MAE)? – Arguments against avoiding RMSE in the literature. Geosci Model Dev. 2014;7(3):1247–50. Available from: https://doi.org/10.5194/gmd-7-1247-2014
4. Inamdar S, Kedar T, Gujar H, Tanpure P, Sapkal S. Harnessing AI and machine learning in pharmaceutical quality assurance. Int J Sci R Tech. 2024;1(11):145-150.
5. TestingXperts. AI in quality assurance [Internet]. [cited 2026 Jan 7]. Available from: https://www.testingxperts.com/blog/ai-in-quality-assurance.
6. Gupta S. The challenges of AI adoption in the pharma sector.

Pharmaceutical Digitalization Journal. 2021;1(2):45–52
7. Kamaraj A, Puranik S. Artificial intelligence in pharmaceutical industry: a review. J Curr Pharm Res. 2023;17(4):13-25.
8. Sun S. Research and development for health products: the role of intellectual property and trade. Bangkok: United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP); 2021 Mar. (ARTNeT Working Paper Series, No. 216). Available from: https://www.unescap.org/sites/default/d8files/knowledge-products/AWP216%20Special%20Series%20on%20Trade%20and%20Health%201_R%26D.pdf
9. Niranjan K, Narayana KS, Rao MVALN. Role of Artifical Intelligence in Logistics and Supply Chain. In: 2021 International Conference on Computer Communication and Informatics (ICCCI); 2021 Jan 27-29; Coimbatore, India. New York: IEEE; 2021. p. 1-3. Available from: https://ieeexplore.ieee.org/document/9402625/
10. Nelson JP, Biddle JB, Shapira P. Applications and societal implications of artificial intelligence in manufacturing: a systematic review [Internet]. arXiv; 2023 [cited 2026 Jan 8]. arXiv:2308.02025 [cs.CY]. Available from: https://arxiv.org/abs/2308.02025.
11. Khalil R, Macdonald JC, Gustafson A, Aljuburi L, Bisordi F, Beakes-Read G. Regulatory considerations for artificial intelligence and machine learning in drug development. Front Med. 2023;10:1233142. doi: 10.3389/fmed.2023.1233142.
12. Lawrence XY, Kopcha M. The future of pharmaceutical quality and the role of the Emerging Technology Team (ETT). Int J Pharm. 2017 Aug 15;528(1-2):354-359. doi: 10.1016/j.ijpharm.2017.06.014
13. Hole G, Hole AS, McFalone-Shaw I. Digitalization in pharmaceutical manufacturing: The role of industry 4.0 and technologies for continuous improvement. Int J Pharm X. 2021 Dec;3:100095. doi: 10.1016/j.ijpx.2021.100095.
14. Walters L. The impact of AI on pharmaceutical quality assurance [Internet]. PharmiWeb.jobs. 2024 Jul 17 [cited 2026 Jan 8]. Available from: https://www.pharmiweb.jobs/article/the-impact-of-ai-on-pharmaceutical-quality-assurance/
15. Salunke AS, Kulkarni SR, Zade KS, Ahirrao MK, Shirsath MR. Automation and AI in Pharmaceutical Quality Assurance: A Review. Int J Innov Res Technol. 2025 Feb;11(9):1744-1748.
16. Kasurde AS, Chopade V. The Impact of Artificial Intelligence (AI) on Quality Assurance. Int Res J Mod Eng Tech Sci. 2024 Nov;6(11):4108-4122.
17. Owen A, Hannah J. Automated Quality Assurance Using AI and Computer Vision. ResearchGate [Preprint]. 2021 Jan. Available from: https://www.researchgate.net/publication/390266338
18. Pol SS, Pawar SS, Balte UM, Thavare RB. Applications of Artificial Intelligence and Machine Learning in Quality Assurance. Int J Res Publ Rev. 2025 Mar;6(3):2917-2921.
19. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, Sangnim T. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci. 2024;203:106938. doi:10.1016/j.ejps.2024.106938.
20. Parmar T. Artificial intelligence in high-tech manufacturing: a review of applications in quality control and process optimization. Int J Innov Res Eng Multidiscip Phys Sci. 2022;10(6). doi:10.37082/IJIRMPS.v10.i6.231961.

21. Khinvasara T, Ness S, Shankar A. Leveraging artificial intelligence for enhanced quality assurance in medical device manufacturing. Asian J Res Comput Sci. 2024;17(6):13–35. doi:10.9734/AJRCOS/2024/v17i6454.
22. Patel P. Impact of artificial intelligence on manufacturing and quality assurance in medical device and pharmaceuticals industry. Int J Innov Technol Explor Eng. 2024;13(8). doi:10.35940/ijitee.I9949.13090824.
23. Bhosale A, Sawant A, Kamble T, Chougule N. Exploring the role of artificial intelligence in modernizing quality assurance and quality control in the pharmaceutical sector. Int J Pharm Sci. 2024;2(11):522–529. doi:10.5281/zenodo.14062391.
24. Saha GC, Eni LN, Saha H, Parida PK, Rathinavelu R, Jain SK, Haldar B. Artificial intelligence in pharmaceutical manufacturing: enhancing quality control and decision making. Riv Ital Filos Analitica Junior. 2023;14(2):116–117.
25. Momin AR, Chavan SM, Datkhile SV, Lokhande RP. Application of artificial intelligence and machine learning in quality assurance. Int J Pharm Sci. 2025;3(3):18–25. doi:10.5281/zenodo.14950226.
26. Kothamali PR, Banik S. Leveraging machine learning algorithms in quality assurance for predictive defect tracking and risk management. *Int J Adv Eng Technol Innov*. 2019;1(2):103–121.
27. Hoffmann R, Reich C. A systematic literature review on artificial intelligence and explainable artificial intelligence for visual quality assurance in manufacturing. Electronics. 2023;12:4572. doi:10.3390/electronics12224572.
28. Kausik AK, Rashid AB, Baki RF, Maktum MMJ. Machine learning algorithms for manufacturing quality assurance: a systematic review of performance metrics and applications. Array. 2025;26:100393. doi:10.1016/j.array.2025.100393.
29. Ranebennur R, Thirumaleshwar S, Somareddy HK, Desai R, Sandeep DS. Development of automated quality assurance systems for pharmaceutical manufacturing: a review. J Clin Lab Med Microbiol. 2023;1(11):1855–1864
30. Gandu S, Gandla K, Vaishnavi M, Repudi L. A review on implementation of automation in the pharmaceutical industries. World J Adv Res Rev. 2023;18(2):606–615. doi:10.30574/wjarr.2023.18.2.0858.
31. Warrier AS. Automation in pharmaceutical quality assurance: a comprehensive review. Bombay Technologist. 2024;146–161.
32. Shailaja P, Ponnada VNL. A review on robotic process automation in pharmaceutical industry. World J Pharm Res. 2024;13(5):152–163. doi:10.20959/wjpr20245-31303.
33. John A. Enhancing pharmaceutical process efficiency and innovation through the integration of intelligent process automation and generative AI. ResearchGate Preprint. 2025 Feb 7.
34. Mundhra S, Kadiri SK, Tiwari P. Harnessing AI and Machine Learning in Pharmaceutical Quality Assurance. J Pharm Qual Assur Qual Control. 2024 Jan-Jun;6(1):19-29.
35. Lokesh U, Jaswanth B, Rao CB. Automation and robotics in pharmaceutical industry. J Mod Tech Biol Allied Sci. 2025;2(1):26–31. doi:10.70604/jmtbas.v2i1.51.
36. Kauppinen H. Computerized systems' role determination in pharmaceutical manufacturing process [master's thesis]. Tampere: Tampere University; 2024.
37. Ashok L, Murthy BR. Real-time measurement and monitoring of industrial pharmaceutical chemical reactor process parameters using PLC and SCADA system. Int J Eng Res Technol. 2020;9(7):1–6.

38. Parapalli SL. 21 CFR Part 11 compliance in MES: electronic signatures and data integrity. Int J Netw Secur. 2025;5(1):187–201. doi:10.55640/ijns-05-01-11.
39. Stasevych M, Zvarych V. Innovative robotic technologies and artificial intelligence in pharmacy and medicine: paving the way for the future of health care—a review. Big Data Cogn Comput. 2023;7:147. doi:10.3390/bdcc7030147.
40. Ramamoorthy SP. Role of AI, automation and robotics in pharmaceutical industry. J Next-Generation Res 5.0. 2024;1(1):1–8.
41. Raviteja MN, Gupta NV. A review on electronic data management in pharmaceutical industry. Asian J Pharm Clin Res. 2013;6(3):1–6.
42. Kodumuru R, Sarkar S, Parepally V, Chandarana J. Artificial intelligence and internet of things integration in pharmaceutical manufacturing: a smart synergy. Pharmaceutics. 2025;17:290. doi:10.3390/pharmaceutics17030290.
43. Koduri NK, Piridi S. Automating pharmaceutical compliance workflows using RPA and low-code AI. Front Health Inform. 2020;9:266–282. doi:10.5281/zenodo.15623770.
44. Sohoni AP. AI-driven efficiency in pharmaceutical manufacturing: enhancing productivity, compliance, and decision-making. Int J Multidiscip Sci Arts. 2024;3(4):298–305. doi:10.47709/ijmdsa.
45. Gade SH, Ranshur VS, Tarkase KN, Pawar NS. Automation of documentation in pharmaceutical industry. Int J Creat Res Thoughts. 2024;12(9):d539–d556.
46. Global Journal of Medical Case Reports, 2022, 2, 1275 www.scipublications.com/journal/index.php/gjmcr. DOI: 10.31586/gjmcr.2022.1275
47. DeCouto, Victor and Singh, S, "Electronic Validation in the Pharmaceutical Industry" (2016). Mathematics and Computer Science Capstones. 28. http://digitalcommons.lasalle.edu/mathcompcapstones/28
48. Rusjan B. Computer system validation. Management [Internet]. 2020 Dec 21;25(2):1–23. Available from: https://doi.org/10.30924/mjcmi.25.2.1 DOI: https://doi.org/10.30924/mjcmi.25.2.1
49. Van Den Bulck S, De Burghgraeve T, Raat W, Mamouris P, Coursier P, Vankrunkelsven P, et al. The effect of automated audit and feedback on data completeness in the electronic health record of the general physician: protocol for a cluster randomized controlled trial. Trials [Internet]. 2021 May 4;22(1). Available from: https://doi.org/10.1186/s13063-021-05259-9
50. Physiologically Based Pharmacokinetic model qualification and reporting procedures for regulatory submissions: A consortium Perspective [Internet]. Vol. 104, CPT: Pharmacometrics & Systems Pharmacology. 2018 Feb. Report No.: 1. Available from: https://doi.org/10.1002/cpt.1013
51. PHARMACEUTICAL INSPECTION CONVENTION, PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. GOOD PRACTICES FOR COMPUTERISED SYSTEMS IN REGULATED "GXP" ENVIRONMENTS. PIC/S, editor. 2007 Sep.
52. Staib E, Williams TG, Siôn Wyn. APPLYING GAMP® CONCEPTS to machine learning. GAMP®. 2023;15.
53. Pedro F, Veiga F, Mascarenhas-Melo F. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it? Drug Discov Today. 2023;28(11):103759.
54. Nakajima T, Simonetta A. Concept of quality digital twin in agile development [Internet]. 4th

International Workshop on Experience with SQuaRE Series and its Future Direction. CEUR Workshop Proceedings; 2022. Available from: http://ceur-ws.org
55. Böttjer T, Blasco Román S, Copenhagen Business School and The LEGO Group, Aarhus University and The LEGO Group. Conceptual Digital Twin Framework for Quality assurance in the injection molding Industry: Technical and Digital skill Perspectives. ENBIS Spring Meeting 2023. 2023 May
56. Lopes MR, Costigliola A, Pinto R, Vieira S, Sousa JMC. Pharmaceutical quality control laboratory digital twin – A novel governance model for resource planning and scheduling. International Journal of Production Research [Internet]. 2019 Nov 7;58(21):6553–67. Available from: https://doi.org/10.1080/00207543.2019.1683250
57. Milisavljevic-Syed, J., Khan, M., Xia, H., Li, J., & Salonitis, K. (2024). Charting the course: Standardization of quality assurance in Digital twin Applications across Product Lifecycle. *Procedia CIRP*, *130*, 718–723. https://doi.org/10.1016/j.procir.2024.10.154